Disease-Vaccine-Landing-Page/Pneumococcal/vaccine-history

In June 2021, Wyeth pharmaceuticals received FDA approval for Prevnar 20 (PCV20) vaccine, a 20-valent pneumococcal conjugate vaccine, which added seven additional strains (8, 10A, 11A, 12F, 15B, 22F, and...

In December of 2011, the FDA approved the expanded use of PCV13 under an “Accelerated Approval” process to include adults 50 years of age and older. The “Accelerated Approval” process...

Vaccine manufacturers responded to the emergence of multiple antibiotic-resistant strains of S. pneumoniae by introducing new pneumococcal vaccines containing additional strains. In March 2009, Synflorix (PCV10), a 10-valent pneumococcal conjugate...

As pneumococcal polysaccharide vaccines were found to be ineffective in children under the age of two, vaccine development continued. Pneumococcal related deaths were reported to be uncommon among children except...

Pneumococcal vaccine development resumed again in 1968, this time at the insistence of National Institutes of Health (NIH) scientist Dr. Robert Austrian. Austrian had witnessed numerous antibiotic treatment failures in...

Pneumococcal capsular polysaccharides were discovered in 1916-1917, but it took researchers until 1927 to realize that the polysaccharides could induce an immune response. The first pneumococcal polysaccharide vaccine contained pneumococcal...

The first pneumococcal vaccine trials began in South Africa in 1911 and involved miners who were administered a whole-cell vaccine consisting of the known circulating strains of pneumococcal. The results...